Taylor H R, Trpis M, Cupp E W, Brotman B, Newland H S, Soboslay P T, Greene B M
International Center for Epidemiologic and Preventive Ophthalmology, Wilmer Institute, Johns Hopkins University, Baltimore, Maryland 21205.
Am J Trop Med Hyg. 1988 Jul;39(1):86-90. doi: 10.4269/ajtmh.1988.39.86.
Ivermectin was tested for possible prophylactic action against the third and fourth larval stages (L3 and L4) of Onchocerca volvulus inoculated into chimpanzees. The infective larvae (L3) were obtained from laboratory-raised black flies. Eighteen chimpanzees were inoculated, each with approximately 250 L3. Six were treated with ivermectin (200 micrograms/kg) on the day of inoculation, 6 were treated with ivermectin on day 28, and 6 were not treated. Monthly skin snips were taken for the next 30 months to detect patent infection. One of the chimpanzees treated with ivermectin on the day of infection developed a patent infection as did 4 of the 6 treated at day 28 and 4 of the 6 control animals. The results suggest that ivermectin may have a partial in vivo effect against the L3 of O. volvulus but has no effect against later larval stages of the parasite.
对伊维菌素针对接种到黑猩猩体内的盘尾丝虫第三和第四幼虫阶段（L3和L4）的可能预防作用进行了测试。感染性幼虫（L3）取自实验室饲养的黑蝇。给18只黑猩猩接种，每只接种约250条L3。6只在接种当天用伊维菌素（200微克/千克）治疗，6只在第28天用伊维菌素治疗，6只未治疗。在接下来的30个月里每月进行皮肤活检以检测显性感染。感染当天用伊维菌素治疗的黑猩猩中有1只出现了显性感染，第28天治疗的6只中有4只以及6只对照动物中有4只出现了显性感染。结果表明，伊维菌素可能对盘尾丝虫L3有部分体内作用，但对该寄生虫的后期幼虫阶段没有作用。
